Antifungal therapeutic drug monitoring: established and emerging indications

Andes, David; Pascual, Andres; Marchetti, Oscar

doi:10.1128/aac.00705-08

Cited by 490Antifungal resistance and susceptibilityAntibiotics Pharmacokinetics and EfficacyFungal Infections and Studies

Antifungal therapeutic drug monitoring: established and emerging indications

Open access

Andes, David, Pascual, Andres, Marchetti, Oscar·2009·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.00705-08PMC PMC2612175

Open this paper in CoChat — free account

Abstract

The successful management of invasive fungal infections continues to pose a difficult challenge to clinicians. As the population of at-risk immunocompromised patients increases, the incidence of invasive mycosis has risen in parallel (57). Despite recent advances in antifungal pharmacology, the morbidity and mortality due to invasive fungal infections remain unacceptably high. Numerous factors determine the outcome of these infections, including the host immune state, pathogen variables including drug susceptibility, location of the infection, timing of diagnosis relative to initiation of antifungal therapy, management of the infection source (e.g., surgery or vascular catheter removal), and effective administration of the appropriate dose of the most potent and safe antifungal drug (Fig. (Fig.1).1). Few of these variables are under the control of the clinician. The choices of antifungal drug and dosing regimen are among the factors which the clinician can dictate. However, even if the appropriate drug and regimen are initiated, drug exposure at the site of infection may be inadequate due to pharmacokinetic variability and may contribute to treatment failure. Conversely, antifungal exposures may exceed those anticipated and may result in toxicity. Many antifungal drugs exhibit marked variability in drug blood concentrations due to inconsistent absorption, metabolism, elimination, or interaction with concomitant medications. An understanding of the pharmacokinetics and pharmacodynamics of these drugs has been demonstrated to be important to optimize drug choice and dosing regimen design. One tool to detect drug exposures outside of the therapeutic window is monitoring of drug concentration in blood. The utility of this tool to inform drug choice and dosing decisions is being increasingly explored. FIG. 1. Determinants for outcome of invasive mycoses. Several factors must be considered in determining the role of therapeutic drug monitoring in patient management (32, 86, 88). An accurate, rapid, and cost-effective drug assay must be readily available to the clinician. Two pharmacological features then determine the relevance of monitoring of concentrations of drug in blood. The foremost variable is an unpredictable drug dose-exposure relationship. Next, there must be a clear relationship between concentrations of drug in blood and either toxicity or treatment efficacy. Consideration of these pharmacological variables for available antifungal compounds is the focus of this review.

Integrity signals

Registry

Crossref · 10.1128/aac.00705-08

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The PK/PD congruency in target AUC/MIC between Aspergillus and Candida suggests target trough concentrations should be at least 1 to 2 mg/mL for invasive candidiasis and concentration monitoring might be useful in the critical care setting.
“Although not well studied in IC, the PK/PD congruency in target AUC/MIC between Aspergillus and Candida would suggest target trough concentrations should be at least 1 to 2 mg/mL for IC and concentration monitoring might be useful in the critical care setting.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [155]

Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,408 · see citing works
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P. H., Langston, A. A., Tarantolo, S., Greinix, H., de Azevedo, W. M., Reddy, V. S., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,339 · see citing works
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887 · see citing works
Self-citation
A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis
Bennett, J. E., Dismukes, W. E., Duma, R. J., Medoff, G., Sande, M. A., Gallis, H. A., Leonard, J. M., Fields, B. T., Bradshaw, M. W., Haywood, H. B., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197907193010303 · Cited by 861 · see citing works
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855 · see citing works
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · see citing works
Voriconazole: A New Triazole Antifungal Agent
Johnson, L. B., & Kauffman, C. A. (2003) · Clinical Infectious Diseases · doi:10.1086/367933 · Cited by 782 · see citing works
Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial
Walsh, T. J., RAAD, I. I., Patterson, T. F., Chandrasekar, P. H., Donowitz, G. R., Graybill, R. J., Greene, R. E., Hachem, R. Y., Hadley, S., Herbrecht, R., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 749 · see citing works
Pharmacokinetics and Tissue Penetration of Fluconazole in Humans
Brammer, K. W., Farrow, P. R., & Faulkner, J. K. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s318 · Cited by 430 · see citing works
Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six Weeks
Dismukes, W. E., Cloud, G. A., Gallis, H. A., Kerkering, T. M., Medoff, G., Craven, P. C., Kaplowitz, L. G., Fisher, J. F., Gregg, C. R., Bowles, C. A., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708063170602 · Cited by 416 · see citing works
Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens
Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J., & Kleinermans, D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2546-2553.2002 · Cited by 415 · see citing works
Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with Aspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study
Walsh, T. J., Goodman, J. L., Pappas, P. G., Bekersky, I., Buell, D. N., Roden, M. M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401 · see citing works
Voriconazole therapeutic drug monitoring
Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1570-1572.2006 · Cited by 399 · see citing works
Self-citation
Identification of the Cytochrome P450 Enzymes Involved in the N-Oxidation of Voriconazole
Hyland, R., Jones, B. C., & Smith, D. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.540 · Cited by 383 · see citing works
Treatment of invasive aspergillosis with itraconazole
Denning, D. W., TUCKER, R. M., Hansen, L., & Stevens, D. A. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90475-0 · Cited by 364 · see citing works
Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration
Walsh, T. J., Karlsson, M. O., Driscoll, T., Arguedas, A. G., Adamson, P. C., Sáez‐Llorens, X., Vora, A. J., Arrieta, A. C., Blumer, J. L., Lutsar, I., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2166-2172.2004 · Cited by 337 · see citing works
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults
Courtney, R., Wexler, D. B., Radwanski, E., Lim, J. M., & Laughlin, M. A. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01977.x · Cited by 328 · see citing works
Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.828-833.2002 · Cited by 320 · see citing works
Pharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R. E., Lewis, J. S., Martin, C. A., & Andes, D. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 311 · see citing works
Self-citation
Pharmacokinetics of itraconazole following oral administration to normal volunteers
Hardin, T. C., Graybill, J. R., Fetchick, R. J., Woestenborghs, R. J. H., Rinaldi, M. G., & Kuhn, J. G. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.9.1310 · Cited by 299 · see citing works
Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection
Ullmann, A. J., Cornely, O. A., Burchardt, A. C., Hachem, R. Y., Kontoyiannis, D. P., Toepelt, K., Courtney, R., Wexler, D. B., Krishna, G., Martinho, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.658-666.2006 · Cited by 271 · see citing works
Correlation of MIC with Outcome for <i>Candida</i> Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints
Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258 · see citing works
Self-citation
Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities
Tan, K., Brayshaw, N., Tomaszewski, K. E., Troke, P. F., & Wood, N. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005283837 · Cited by 256 · see citing works
Mode of action of 5-fluorocytosine and mechanisms of resistance
Polak, A., & Scholer, H. J. (2009) · Chemotherapy · doi:10.1159/000221854 · Cited by 250 · cited 1× · see citing works
“Use in other situations has been limited due to clinician concerns regarding drug toxicity and resistance development with monotherapy administration (35, 67, 73).”
Background
Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men
Stone, J. A., Holland, S. D., Wickersham, P. J., Sterrett, A. T., Schwartz, M. S., Bonfiglio, C. A., Hesney, M., Winchell, G. A., Deutsch, P., Greenberg, H. E., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.739-745.2002 · Cited by 246 · see citing works
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis
Stamm, A. M., Diasio, R. B., Dismukes, W. E., Shadomy, S., Cloud, G. A., Bowles, C. A., Karam, G. H., & Espinel‐Ingroff, A. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90691-7 · Cited by 243 · see citing works
Evolving Role of Flucytosine in Immunocompromised Patients: New Insights into Safety, Pharmacokinetics, and Antifungal Therapy
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232 · see citing works
In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3165-3169.2003 · Cited by 231 · see citing works
Self-citation
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy
Trifilio, S. M., Bennett, C. L., Yarnold, P. R., McKoy, J. M., Parada, J. P., Mehta, J., Chamilos, G., Palella, F. J., Kennedy, L. D., Mullane, K. M., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705614 · Cited by 228 · see citing works
Posaconazole: A Broad-Spectrum Triazole Antifungal Agent
Nagappan, V., & Deresinski, S. C. (2007) · Clinical Infectious Diseases · doi:10.1086/523576 · Cited by 223 · see citing works
Cost-Effectiveness of Therapeutic Drug Monitoring
Touw, D. J., Neef, C., Thomson, A. H., & Vinks, A. A. T. M. M. (2005) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200502000-00004 · Cited by 218 · see citing works
Itraconazole Therapy for Cryptococcal Meningitis and Cryptococcosis
Denning, D. W. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100107024 · Cited by 210 · see citing works
Oral Bioavailability of Posaconazole in Fasted Healthy Subjects
Ezzet, F., Wexler, D. B., Courtney, R., Krishna, G., Lim, J. M., & Laughlin, M. A. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00006 · Cited by 208 · see citing works
Enhanced Bioavailability of Itraconazole in Hydroxypropylβ-Cyclodextrin Solution versus Capsules in Healthy Volunteers
Barone, J. A., Moskovitz, B. L., Guarnieri, J. A., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., & Jessen, L. M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1862 · Cited by 207 · see citing works
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
Trifilio, S. M., Pennick, G. J., Pi, J., Zook, J., Golf, M., Kaniecki, K., Singhal, S., WILLIAMS, S. F., Winter, J. N., Tallman, M. S., et al. (2007) · Cancer · doi:10.1002/cncr.22568 · Cited by 198 · see citing works
Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft‐versus‐Host Disease
Krishna, G., Martinho, M., Chandrasekar, P. H., et al. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.12.1627 · Cited by 195 · see citing works
Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model
Andes, D., & van Ogtrop, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2116 · Cited by 192 · see citing works
Self-citation
Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels
Boogaerts, M. A., Verhoef, G. E. G., Zachée, P., Demuynck, H., Verbist, L., & Beule, K. D. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02299.x · Cited by 189 · see citing works
Adverse Reactions to Voriconazole
Boyd, A. E., Modi, S., Howard, S. J., Moore, C. B., Keevil, B. G., & Denning, D. W. (2004) · Clinical Infectious Diseases · doi:10.1086/424662 · Cited by 182 · see citing works
Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction
Hébert, M. F., Smith, H. E., Marbury, T. C., Swan, S. K., Smith, W. B., Townsend, R. W., Buell, D. N., Keirns, J. J., & Bekersky, I. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005279580 · Cited by 181 · see citing works
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
Trifilio, S. M., Ortiz, R., Pennick, G. J., Verma, A., Pi, J., Stosor, V., Zembower, T., & Mehta, J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704828 · Cited by 180 · see citing works
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Andes, D., Stamsted, T., & Conklin, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.922-926.2001 · Cited by 180 · see citing works
Self-citation
Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study
Lazarus, H. M., Blumer, J. L., Yanovich, S., Schlamm, H. T., & Romero, A. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011445 · Cited by 179 · see citing works
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.137-142.2004 · Cited by 177 · see citing works
Self-citation
The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects
Peer, A. V., Woestenborghs, R., Heykants, J., Gasparini, R., & Gauwenbergh, G. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00558308 · Cited by 176 · see citing works
Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia
Clancy, C. J., Yu, V. L., Morris, A. J., Snydman, D. R., & Nguyen, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3171-3177.2005 · Cited by 176 · see citing works
Optimisation of Itraconazole Therapy Using Target Drug Concentrations
Poirier, M., & CHEYMOL, G. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835060-00004 · Cited by 172 · see citing works
Population Pharmacokinetic Analysis of Anidulafungin, an Echinocandin Antifungal
Dowell, J. A., Knebel, W., Ludden, T., Stogniew, M., Krause, D., & Henkel, T. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004265644 · Cited by 169 · see citing works
Pharmacokinetics of voriconazole and cytochrome p450 2C19 genetic status
Ikeda, Y. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.02.002 · Cited by 163 · see citing works
Ketoconazole vs. Itraconazole for Antifungal Prophylaxis in Patients with Severe Granulocytopenia: Preliminary Results of Two Nonrandomized Studies
Thicot, G., Joosten, E., Boogaerts, M. A., Pitte, J. V., & Cauwenbergh, G. F. M. J. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.supplement_1.s94 · Cited by 162 · see citing works
Cost-effectiveness of therapeutic drug monitoring.
Dm, G., & Hardy, B. G. (1990) · PubMed · Cited by 161 · see citing works
Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia
Pai, M. P., Turpin, R. S., & Garey, K. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-06 · Cited by 160 · see citing works
High-dose itraconazole in the treatment of severe mycoses
Sharkey, P. K., Rinaldi, M. G., Dunn, J. F., Hardin, T. C., Fetchick, R. J., & Graybill, J. R. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.707 · Cited by 155 · see citing works
Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection
Krishna, G., Sansone‐Parsons, A., Martinho, M., Kantesaria, B. S., & Pedicone, L. D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00454-06 · Cited by 155 · see citing works
Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring
Imhof, A., Schaer, D. J., Schwarz, U., & Schanz, U. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11547 · Cited by 152 · see citing works
Bone Marrow Toxicity Associated with 5-Fluorocytosine Therapy
Kauffman, C. A., & Frame, P. T. (1977) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.11.2.244 · Cited by 152 · see citing works
Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety
Purkins, L., Wood, N., Greenhalgh, K., Allen, M. J., & Oliver, S. D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01993.x · Cited by 149 · see citing works
Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole
Glasmacher, A. G., Hahn, C., Leutner, C., Molitor, E., Wardelmann, E., Losem, C. J., Sauerbruch, T., Marklein, G., & Schmidt‐Wolf, I. G. H. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00505.x · Cited by 147 · see citing works
Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients
Gubbins, P. O., Krishna, G., Sansone‐Parsons, A., Penzak, S. R., Li, D., Martinho, M., & Anaissie, E. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-06 · Cited by 146 · see citing works
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., & Hou, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-07 · Cited by 140 · see citing works
Self-citation
Effect of a Cola Beverage on the Bioavailability of Itraconazole in the Presence of H2 Blockers
Lange, D., Pavao, J. H., Wu, J., & Klausner, M. A. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04332.x · Cited by 136 · see citing works
Development and Validation of a High-Performance Liquid Chromatography Assay for Voriconazole
Pennick, G. J., Clark, M., Sutton, D. A., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2348-2350.2003 · Cited by 130 · see citing works
Itraconazole in Cyclodextrin Solution
Stevens, D. A. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.8.603.31529 · Cited by 129 · see citing works
Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole
Jaruratanasirikul, S., & Kleepkaew, A. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050280 · Cited by 128 · see citing works
Invasive Fungal Infections
Gullo, A. (2009) · Drugs · doi:10.2165/11315530-000000000-00000 · Cited by 127 · see citing works
Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis.
Cartledge, J. D., Midgely, J., & Gazzard, B. G. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.6.477 · Cited by 126 · see citing works
Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole.
de Velde, V. J. V., Peer, A. P. V., Heykants, J., Woestenborghs, R. J. H., Rooy, P. V., Beule, K. D., & Cauwenbergh, G. F. M. J. (1996) · PubMed · Cited by 116 · see citing works
Flucytosine kinetics in subjects with normal and impaired renal function
Cutler, R. E., Blair, A. D., & Kelly, M. R. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978243333 · Cited by 109 · see citing works
Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases
Hong, Y., Shaw, P. J., Nath, C. E., Yadav, S. P., Stephen, K. R., Earl, J. W., & McLachlan, A. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.935-942.2006 · Cited by 102 · see citing works
Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl‐β‐cyclodextrin oral solution or coated‐pellet capsules
Glasmacher, A. G., Hahn, C., Molitor, E., Marklein, G., Sauerbruch, T., & Schmidt‐Wolf, I. G. H. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00518.x · Cited by 101 · see citing works
Effect of Food on the Pharmacokinetics of a New Hydroxypropyl‐β‐Cyclodextrin Formulation of Itraconazole
de Velde, V. J. S. V., Peer, A. P. V., Heykants, J., Woestenborghs, R. J. H., Rooy, P. V., Beule, K. D., & Cauwenbergh, G. F. M. J. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb02973.x · Cited by 99 · see citing works
In Vivo Characterization of the Pharmacodynamics of Flucytosine in a Neutropenic Murine Disseminated Candidiasis Model
Andes, D. R., & van Ogtrop, M. L. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.938-942.2000 · Cited by 97 · see citing works
Self-citation
Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods
Pascual, A., Nieth, V., Calandra, T., Billé, J., Bolay, S., Decosterd, L. A., Buclin, T., Majcherczyk, P. A., Sanglard, D., & Marchetti, O. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00957-06 · Cited by 96 · see citing works
Self-citation
Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients
Prentice, A., Warnock, D. W., Johnson, S. A., Phillips, M. J., & Oliver, D. A. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.2.247 · Cited by 92 · see citing works
The Safety of Voriconazole
Potoski, B. A., & Brown, J. E. (2002) · Clinical Infectious Diseases · doi:10.1086/343746 · Cited by 87 · see citing works
Flucytosine: Correlation between Toxicity and Pharmacokinetic Parameters
Vermes, A., van der Sijs, H., & Guchelaar, H. (2000) · Chemotherapy · doi:10.1159/000007260 · Cited by 84 · see citing works
Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations
TUCKER, R. M., Denning, D. W., Arathoon, E., et al. (1990) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(90)70261-f · Cited by 82 · see citing works
Safety of Voriconazole and Dose Individualization
Lutsar, I., Hodges, M. R., Tomaszewski, K. E., Troke, P. F., & Wood, N. (2003) · Clinical Infectious Diseases · doi:10.1086/374248 · Cited by 75 · see citing works
Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma
Berenguer, J., Ali, N. A. S., Allende, M. C., Lee, J. K., Garrett, K. F., Battaglia, S., Piscitelli, S. C., Rinaldi, M. G., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.6.1303 · Cited by 74 · see citing works
Pharmacokinetics and Safety of a 7-Day Administration of Intravenous Itraconazole followed by a 14-Day Administration of Itraconazole Oral Solution in Patients with Hematologic Malignancy
Boogaerts, M., Maertens, J. A., van der Geest, R., Bosly, A., Michaux, J., Hoof, A. V., Cleeren, M., Woestenborghs, R. J. H., & Beule, K. D. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.981-985.2001 · Cited by 72 · see citing works
Flucytosine therapeutic monitoring: 15 years experience from the UK
Pasqualotto, A. C., Howard, S. J., Moore, C. B., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl550 · Cited by 71 · see citing works
Pharmacokinetics of fluconazole in renal failure.
Berl, T., Wilner, K. D., Gardner, M., et al. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v62242 · Cited by 64 · see citing works
Drug–drug interactions of antifungal agents and implications for patient care
Gubbins, P. O., & Amsden, J. R. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.13.2231 · Cited by 64 · see citing works
Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration
Yagasaki, K., Gando, S., Matsuda, N., Kameue, T., Ishitani, T., Hirano, T., & Iseki, K. (2003) · Intensive Care Medicine · doi:10.1007/s00134-003-1980-z · Cited by 62 · see citing works
Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections
den Hollander, J. G. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl108 · Cited by 60 · see citing works
Therapeutic drug monitoring of systemic antifungal therapy
Summers, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.6.753 · Cited by 56 · see citing works
Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions
Hurlé, A. D.-G., Navarro, A. S., & Sánchez, M. J. G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01611.x · Cited by 51 · see citing works
Altered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis
Weiler, S., Zoller, H., Graziadei, I. W., Vogel, W., Bellmann‐Weiler, R., Joannidis, M., & Bellmann, R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00791-07 · Cited by 50 · see citing works
Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine againstCandida albicansand Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect
Hope, W. W., Warn, P. A., Sharp, J., Howard, S. J., Kasai, M., Louie, A., Walsh, T. J., Drusano, G. L., & Denning, D. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00369-06 · Cited by 49 · see citing works
Voriconazole plasma monitoring
Pasqualotto, A. C., Shah, M. J., Wynn, R., et al. (2008) · Archives of Disease in Childhood · doi:10.1136/adc.2007.118844 · Cited by 47 · see citing works
HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases
Müller, C., Arndt, M., Queckenberg, C., Cornely, O. A., & Theisohn, M. (2006) · Mycoses · doi:10.1111/j.1439-0507.2006.01297.x · Cited by 41 · see citing works
Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations.
Poirier, J., Berlioz, F., Isnard, F., & CHEYMOL, G. (1996) · PubMed · Cited by 40 · see citing works
Liver Failure in a Child Receiving Highly Active Antiretroviral Therapy and Voriconazole
Scherpbier, H. J., Hilhorst, M. I., & Kuijpers, T. W. (2003) · Clinical Infectious Diseases · doi:10.1086/376985 · Cited by 35 · see citing works
Progressive fusariosis: Unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection
Lewis, R. J., Hogan, H., Howell, A., et al. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701724819 · Cited by 32 · see citing works
Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients
Mohammédi, I., Piens, M. A., Padoin, C., & Robert, D. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-1325-7 · Cited by 30 · see citing works
Random plasma concentrations of voriconazole decline over time
Mulanovich, V. E., Lewis, R. E., RAAD, I. I., & Kontoyiannis, D. P. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.07.019 · Cited by 26 · see citing works
Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients
Csajka, C., Decosterd, L. A., Buclin, T., et al. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0377-6 · Cited by 22 · see citing works
Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study.
de la Vega, S. L., Volkow, P., Yeates, R. A., & Pfaff, G. (1994) · PubMed · Cited by 21 · see citing works
Going From Genome to Pill
Service, R. F. (2005) · Science · doi:10.1126/science.308.5730.1858 · Cited by 19 · see citing works
How Does a Patient Maximally Benefit from Anti-infective Chemotherapy?
Drusano, G. L. (2004) · Clinical Infectious Diseases · doi:10.1086/424673 · Cited by 17 · see citing works
Breakthrough <i>Candida</i> Infections in Patients Receiving Voriconazole
Gerzenshtein, L., Patel, S. M., Scarsi, K. K., Postelnick, M. J., & Flaherty, J. P. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e627 · Cited by 15 · see citing works

Flagged first, then by citations

Sorted by citations

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Self-citation
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926 · see citing works
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556 · see citing works
Self-citation
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055 · see citing works
ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.
Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., Jensen, H. E., Lass-Flörl, C., Richardson, M. D., Akova, M., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12038 · Cited by 386 · see citing works
Antifungal Agents
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351 · see citing works
Self-citation
Breakthrough invasive fungal infections: Who is at risk?
Jenks, J. D., Cornely, O. A., Chen, S. C. ‐., Thompson, G. R., & Hoenigl, M. (2020) · Mycoses · doi:10.1111/myc.13148 · Cited by 191 · see citing works
A marine microbiome antifungal targets urgent-threat drug-resistant fungi
Zhang, F., Zhao, M., Braun, D. R., Ericksen, S. S., Piotrowski, J. S., Nelson, J., Peng, J., Ananiev, G. E., Chanana, S., Barns, K., et al. (2020) · Science · doi:10.1126/science.abd6919 · Cited by 177 · see citing works
Self-citation
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
Kofla, G., & Ruhnke, M. (2011) · European Journal of Medical Research · doi:10.1186/2047-783x-16-4-159 · Cited by 153 · see citing works
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134 · see citing works
Self-citation
Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009)
Espinel-Ingroff, A. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70004-x · Cited by 105 · see citing works
New generation azole antifungals in clinical investigation
Girmenia, C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903176407 · Cited by 107 · see citing works
Management of invasive fungal infections: a role for polyenes
Chandrasekar, P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq479 · Cited by 100 · see citing works
Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy
Zhang, L., Xiao, M., Watts, M. R., Wang, H., Fan, X., Kong, F., & Xu, Y.-C. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1086-6 · Cited by 62 · see citing works
Optimizing antifungal choice and administration
Andes, D. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761135 · Cited by 63 · see citing works
Self-citation
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62 · see citing works
Self-citation
Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: A systematic review.
Sinnollareddy, M., Peake, S. L., Roberts, M. S., Lipman, J., & Roberts, J. A. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.07.013 · Cited by 56 · see citing works
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35 · see citing works

Authors: Andes, D., Pascual, A., & Marchetti, O.
Affiliations: University of Wisconsin–Madison (US)
Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH-1011 Lausanne, Switzerland
Centre Hospitalier Universitaire Vaudois (CH)
ORCID: Andes, David
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2009-01
Volume: 53
Issue: 1
Pages: 24-34
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.00705-08
PMC: PMC2612175
OpenAlex: W2014557179
Cited by: 490
References: 101
Citations by year: 2026: 8 · 2025: 10 · 2024: 16 · 2023: 17 · 2022: 19 · 2021: 24 · 2020: 27 · 2019: 28 · 2018: 20 · 2017: 34 · 2016: 34 · 2015: 34 · 2014: 46 · 2013: 26 · 2012: 46
FWCI: 3.87
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords: antifungal agents, therapeutic drug monitoring, invasive fungal infections, antifungal pharmacokinetics, pharmacodynamics, dosing regimen, immunocompromised patients, antifungal toxicity, drug exposure, drug sensitivity
MeSH terms: Antifungal Agents, Drug Monitoring

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antifungal therapeutic drug monitoring: established and emerging indications

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks